Cite
EE222 Evaluating the Budget Impact on the Health Care System in England and Wales of RefluxStop as a Treatment for Refractory Gastroesophageal Reflux Disease (GORD).
MLA
Shore, J., et al. “EE222 Evaluating the Budget Impact on the Health Care System in England and Wales of RefluxStop as a Treatment for Refractory Gastroesophageal Reflux Disease (GORD).” Value in Health, vol. 25, no. 12, Dec. 2022, pp. S96–97. EBSCOhost, https://doi.org/10.1016/j.jval.2022.09.471.
APA
Shore, J., Grodzicki, L., Harper, S., & Mealing, S. (2022). EE222 Evaluating the Budget Impact on the Health Care System in England and Wales of RefluxStop as a Treatment for Refractory Gastroesophageal Reflux Disease (GORD). Value in Health, 25(12), S96–S97. https://doi.org/10.1016/j.jval.2022.09.471
Chicago
Shore, J, L Grodzicki, S Harper, and S Mealing. 2022. “EE222 Evaluating the Budget Impact on the Health Care System in England and Wales of RefluxStop as a Treatment for Refractory Gastroesophageal Reflux Disease (GORD).” Value in Health 25 (12): S96–97. doi:10.1016/j.jval.2022.09.471.